Indication: RSV bronchiolitis
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 36 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sub-indication: RSV
Study Type: Drug Study
Principal Investigator: Kristina Bryant, M.D.Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Enanta Pharmaceuticals, Inc.
Learn more at ClinicalTrials.gov
Email for more information: NCRI-ID@NortonHealthcare.org
